Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) has a beta value of -0.09 and has seen 0.44 million shares traded in the recent trading session. The company, currently valued at $1.05B, closed the recent trade at $4.15 per share which meant it gained $0.05 on the day or 1.21% during that session. The MRVI stock price is -178.55% off its 52-week high price of $11.56 and 2.41% above the 52-week low of $4.05.
The consensus among analysts is that Maravai LifeSciences Holdings Inc (MRVI) is Buy stock at the moment, with a recommendation rating of 2.13. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 7 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.04.
Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) trade information
Sporting 1.21% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the MRVI stock price touched $4.15 or saw a rise of 5.68%. Year-to-date, Maravai LifeSciences Holdings Inc shares have moved -23.86%, while the 5-day performance has seen it change -2.13%. Over the past 30 days, the shares of Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) have changed -13.00%.
Wall Street analysts have a consensus price target for the stock at $22, which means that the shares’ value could jump 81.14% from the levels at last check today. The projected low price target is $10.0 while the price target rests at a high of $25.0. In that case, then, we find that the latest price level in today’s session is -502.41% off the targeted high while a plunge would see the stock gain -140.96% from the levels at last check today.
Maravai LifeSciences Holdings Inc (MRVI) estimates and forecasts
The company’s shares have lost -57.13% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -9.83%.
12 analysts offering their estimates for the company have set an average revenue estimate of 57.79M for the current quarter. 12 have an estimated revenue figure of 63.62M for the next ending quarter. Year-ago sales stood 74.14M and 64.18M respectively for this quarter and the next, and analysts expect sales will shrink by -22.06% for the current quarter and -9.83% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -37.53% over the past 5 years.
MRVI Dividends
Maravai LifeSciences Holdings Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Maravai LifeSciences Holdings Inc (NASDAQ:MRVI)’s Major holders
The top two institutional holders are GTCR LLC with over 20.15 million shares worth more than $144.27 million. As of 2024-06-30, GTCR LLC held 15.2267% of shares outstanding.
The other major institutional holder is 12 WEST CAPITAL MANAGEMENT LP, with the holding of over 13.21 million shares as of 2024-06-30. The firm’s total holdings are worth over $94.59 million and represent 9.9833% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Sep 30, 2024, the former fund manager holds about 2.78% shares in the company for having 3.94 shares of worth $16.3 million while later fund manager owns 3.24 shares of worth $13.43 million as of Nov 30, 2024, which makes it owner of about 2.29% of company’s outstanding stock.
